Evogene
EVGN
23 hedge funds and large institutions have $18.2M invested in Evogene in 2018 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 5 increasing their positions, 4 reducing their positions, and 2 closing their positions.
25% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 4
0.08% more ownership
Funds ownership: 35.32% → 35.4% (+0.08%)
0% more funds holding
Funds holding: 23 → 23 (0)
0% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 2
35% less capital invested
Capital invested by funds: $28.2M → $18.2M (-$9.98M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$146K |
| 2 |
Jane Street
New York
|
+$90.4K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$38.4K |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$35K |
| 5 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
+$24.1K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Barclays
London,
United Kingdom
|
-$153K |
| 2 |
Morgan Stanley
New York
|
-$114K |
| 3 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$25K |
| 4 |
MIH
Meitav Investment House
Bene-Beraq,
Israel
|
-$22.6K |
| 5 |
SWM
Stockman Wealth Management
Billings,
Montana
|
-$8.34K |
EVGN Hedge Fund Activity: Q4 2018 in Review
23 of the 4,505 institutional investors tracked by Wall St. Rank reported a position in Evogene (EVGN) for Q4 2018, worth a combined $18.2M — down 35% from $28.2M a quarter earlier.
Fund positioning in EVGN was balanced in Q4 2018: 2 funds opened new positions, 2 closed out, 5 added to existing stakes and 4 trimmed.
The largest buyer was Vanguard Group, adding an estimated $146K. The largest seller was Barclays, exiting entirely with an estimated $153K sold.
- 23 institutional investors held Evogene (EVGN) as of Q4 2018, unchanged from Q3 2018.
- Funds reported $18.2M of Evogene stock for Q4 2018, down 35% quarter-over-quarter.
- 2 funds opened new Evogene positions in Q4 2018 and 2 closed out, a net change of 0 holders.
- The largest Evogene buyer in Q4 2018 was Vanguard Group, an estimated $146K added.
- The largest Evogene seller in Q4 2018 was Barclays, an estimated $153K sold.
Based on aggregated 13F filings for Q4 2018.